A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Clinical trial NCT06764940 · RECRUITING

Trial details

NCT number: NCT06764940
Sponsor: Biostar Pharma, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-negative Breast Cancer Patients With Brain Metastases

Start date: 2025-07-14
Primary completion: 2027-01-15
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.